Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Reported problem | Injury (n = 228) | Malfunction (n = 424) | P value |
Battery depletion | 9 | 6 | 0.057 |
Generator displacement | 11 | 5 | 0.007 |
Pocket erosion | 9 | 0 | < 0.001 |
Infection | 21 | 0 | < 0.001 |
Pain | 41 | 102 | 0.091 |
Lack of benefit | 70 | 243 | < 0.001 |
Lead problems | 40 | 30 | < 0.001 |
Other | 27 | 9 |
- Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
- URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294